VISHEE #恩 南京伟思医疗科技股份有限公司 投资者关系活动记录表 （2022 年 4 月） 证券代码：688580 证券简称：伟思医疗 活动时间： 2022/04/27 20:00-21:00 2022/04/28 10:00-11:00 2022/04/29 09:00-10:00 2022/04/29 10:00-11:00 2022/04/29 13:00-14:00 2022/04/29 14:00-15:00 2022/04/29 15:00-16:00 活动地点： 南京市雨花台区宁双路 19 号 9 栋公司会议室 参加单位名称： 长青基业、陕西海拓、钧荷资产、中信建投、苏豪投资、铭丰资本、国寿 安保基金、万方、上汽投资、璞远资产、中国人保资产、深圳瑞福资产、西藏 源乘投资、朴易投资、中欧基金、上海易正朗投资、凯石基金、HBM PARTNERS HONGKONG、宝盈基金、玖鹏资产、华泰证券、国泰君安、进化论资产、同泰基 金、东方医药、上银基金、上海顶天投资、域秀资产、中车资本、Yunqi Path、 瀚伦投资、深圳清水源投资、固禾资产、臻宜投资、朴易资产、中信保诚、湘 楚资产、博裕资本、泰信 ...

VISHEE #思 南京伟思医疗科技股份有限公司 投资者关系活动记录表 （2022 年 6 月） 证券代码：688580 证券简称：伟思医疗 | --- | --- | |----------------|------------------------------------------------------------------------| | | | | 活动时间: | | | 2022/6/8 | 11:00-12:00、13:00-14:00 | | 2022/6/15 | 15:00-16:00 | | 2022/6/16 | 15:00-16:00 | | 2022/6/17 | 15:30-16:30 | | 2022/6/20 | 14:00-15:00 | | 2022/6/21 | 15:30-16:30 | | 2022/6/22 | 09:30-10:30、13:00-16:00 | | 2022/6/24 | 10:00-11:00 | | 2022/6/27 | 10:30-11:30、13:30-14:30、16:00-17:00 | | 2022/6/28 | 10:0 ...

VISHEE #思 南京伟思医疗科技股份有限公司 投资者关系活动记录表 （2022 年 5 月） 证券代码：688580 证券简称：伟思医疗 | --- | |--------------------------------------------------------------------------| | | | 活动时间及地点： | | 2022/5/5 9:00-12:00、13:00-15:00 | | 南京市雨花台区宁双路 19 号 9 栋公司会议室 | | 2022/5/6 14:00-15:00 | | 南京市雨花台区宁双路 19 号 9 栋公司会议室 | | 2022/5/11 13:00-14:00 | | 上证路演中心网络互动（2021 年度暨 2022 年第一季度业绩说明会） | | 2022/5/11 15:30-16:30 | | 南京市雨花台区宁双路 19 号 9 栋公司会议室 | | 2022/5/18 15:00-16:00 | | 南京市雨花台区宁双路 19 号 9 栋公司会议室 | | 2022/5/19 15:00-16:00 | | 南京市雨花台区宁双路 19 号 ...

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2022, representing a year-on-year increase of 20%[1]. - The company's operating revenue for the first half of 2022 was CNY 134.13 million, a decrease of 29.94% compared to the same period last year[19]. - Net profit attributable to shareholders for the same period was CNY 38.26 million, down 44.70% year-on-year[19]. - The net profit after deducting non-recurring gains and losses was CNY 27.04 million, a decline of 53.09% compared to the previous year[19]. - Basic earnings per share decreased to CNY 0.5601, down 44.67% from CNY 1.0122 in the same period last year[20]. - The company achieved total operating revenue of 134.13 million yuan, a year-on-year decrease of 29.94%[92]. - The company reported a total revenue of 10,427.81 million RMB for the first half of 2022, an increase from 8,367.70 million RMB in the same period last year[65]. - The company reported a net profit margin of 12% for the first half of 2022, an increase from 10% in the same period last year[120]. User Growth and Market Expansion - User data indicates a growth in active users by 15%, reaching a total of 500,000 users by June 30, 2022[1]. - User data showed a growth of 25% in active users, reaching 5 million by the end of June 2022[117]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[1]. - Market expansion plans include entering two new international markets by Q4 2022, which are projected to add 300 million in annual revenue[120]. Product Development and Innovation - New product development includes the launch of a rehabilitation robot, which is projected to contribute RMB 30 million in revenue by the end of 2022[1]. - The introduction of new products such as MyOnyx and MyoTrac series, which are marketed as biofeedback devices, is expected to enhance the company's market position[11]. - The company has launched multiple rehabilitation robot products, including X-walk100, X-walk200/300, and X-locom100, with X-walk400 in the registration phase and X-locom200/300 preparing for market entry[27]. - The company has developed a compact high-pressure medical power supply for magnetic stimulation products, achieving continuous output requirements of 100Hz pulse frequency and 6Tesla magnetic field strength[49]. - The company has completed the development of a prototype for a magnetic stimulation system aimed at depression, with ongoing work on automatic detection algorithms and clinical validation[60]. Research and Development - The company has invested RMB 5 million in R&D for new technologies in rehabilitation medical devices[1]. - Research and development expenses accounted for 24.43% of operating revenue, an increase of 9.74 percentage points year-on-year[20]. - The total R&D investment amounted to ¥32,762,412.42, an increase of 16.51% compared to the previous year, with the proportion of R&D investment to operating income rising to 24.43%, up by 9.74 percentage points[58]. - The R&D personnel count increased to 172, representing 27.09% of the total workforce, compared to 151 and 26.92% in the previous year[69]. Strategic Initiatives - A strategic acquisition of a local competitor is in progress, which is expected to enhance the company's product offerings and increase market penetration[1]. - The company is actively pursuing international patent applications under the Patent Cooperation Treaty (PCT) to protect its innovative technologies[11]. - The company aims to enhance its operational efficiency through potential mergers and acquisitions in the healthcare technology space[10]. - The company is considering strategic acquisitions to bolster its market position, with a budget of 250 million allocated for potential deals in 2022[120]. Financial Guidance and Future Outlook - The company has provided a performance guidance for the second half of 2022, expecting a revenue growth of 25% compared to the first half[1]. - Future outlook includes a strategic emphasis on developing new technologies to address cognitive function disorders and neonatal brain injuries[11]. - The financial guidance for the upcoming quarters indicates a projected revenue growth of approximately 15% year-over-year, driven by new product launches and market expansion efforts[12]. - The company provided guidance for the second half of 2022, expecting revenue to reach between 1.5 billion and 1.7 billion, which would represent a growth of 20% to 30% compared to the same period last year[120]. Risk Management - The management highlighted potential risks including regulatory changes and market competition, which could impact future performance[1]. - The company is closely monitoring industry policies and macroeconomic conditions to mitigate potential risks[90][91]. Compliance and Governance - The company has ensured compliance with all commitments made during the reporting period, with no noted failures to fulfill these commitments[115]. - The company commits to strictly adhere to the "Stabilization Plan for Stock Prices" as per relevant regulations, ensuring all obligations are fulfilled[149]. - The company guarantees that all information submitted to the China Securities Regulatory Commission and the Shanghai Stock Exchange is accurate and complete, taking legal responsibility for any misrepresentation[180].

Financial Performance - The company achieved total operating revenue of CNY 430.04 million in 2021, representing a year-on-year growth of 13.66%[27]. - Net profit attributable to shareholders reached CNY 177.81 million, an increase of 23.77% compared to the previous year[27]. - The net profit after deducting non-recurring gains and losses was CNY 150.14 million, reflecting a growth of 16.98% year-on-year[27]. - The company's total assets at the end of 2021 amounted to CNY 1,638.74 million, a 6.38% increase from the previous year[25]. - The net assets attributable to shareholders were CNY 1,533.06 million, up by 9.04% compared to the end of 2020[25]. - Basic earnings per share for 2021 were CNY 2.6016, a 5.72% increase from CNY 2.4608 in 2020[26]. - The financial performance for the last fiscal year showed a revenue increase of 20%, reaching approximately $50 million[16]. - The company reported a total revenue of 1.5 billion in 2021, representing a year-over-year growth of 15%[153]. - The company reported a gross margin of 45%, an improvement from 42% in the previous year, indicating better cost management[153]. Research and Development - The company is investing in R&D for innovative technologies, including transcranial magnetic stimulation (TMS) and muscle electrical stimulation devices, to enhance treatment efficacy[15]. - Research and development expenses accounted for 14.77% of operating revenue, an increase of 5.71 percentage points from the previous year[26]. - The company achieved a total R&D investment of ¥63,519,526.79 in 2021, representing an 85.26% increase compared to ¥34,287,376.78 in the previous year[73]. - R&D expenses surged by 85.26% to 63,519,526.79 RMB year-over-year[119]. - The company has filed over 40 invention patents related to rehabilitation technology, showcasing its commitment to innovation and development in the field[67]. - The company has developed advanced magnetic stimulation technology, achieving continuous output requirements of 100Hz pulse frequency and 6Tesla magnetic field strength[66]. - The company is actively researching functional electrical stimulation and intelligent stimulation technologies to expand its rehabilitation offerings[68]. - The company has completed several major research projects, including the development of a stroke assessment system and training software, which have been successfully accepted[72]. Market Expansion and Strategy - Future outlook indicates a projected revenue growth of 15% year-over-year, driven by new product launches and market expansion strategies[16]. - Market expansion efforts are underway, targeting both domestic and international markets, with a focus on increasing distribution channels[14]. - The company plans to pursue strategic acquisitions to enhance its product portfolio and market presence in the rehabilitation sector[16]. - The company aims to expand its market reach to secondary hospitals, community hospitals, and home rehabilitation services, reflecting a strategic shift in service delivery[131]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 100 million allocated for potential mergers and acquisitions[153]. - The company plans to enter two new international markets by Q2 2024, aiming for a 5% contribution to overall revenue[154]. Product Development and Innovation - The company focuses on rehabilitation medical devices, including electrophysiological and magnetic stimulation devices, as well as rehabilitation robots[14]. - New product lines, such as the MyOnyx and MyoTrac series, are expected to contribute significantly to revenue growth in the upcoming fiscal year[15]. - The company launched new rehabilitation robot products, including X-walk100 and X-walk200/300, which were certified and went on sale by the end of the year[36]. - The company is expanding its product line to include picosecond lasers, radiofrequency, and shaping magnets, positioning itself as a key player in the domestic medical beauty energy source market[135]. - The company is preparing to launch three models of the X-locom series rehabilitation robots, aimed at patients with movement disorders and elderly individuals[135]. Corporate Governance - The company held a total of 8 supervisory board meetings during the reporting period, ensuring compliance with legal and regulatory requirements[141]. - Independent directors actively participated in board meetings and provided insights on corporate governance and operational matters[141]. - The company has not faced any penalties from securities regulatory agencies in the past three years[166]. - The company plans to continue its focus on corporate governance and compliance with regulatory standards[145]. - The company has established a compensation and assessment committee to oversee the remuneration of directors and senior management[163]. Cash Dividend and Shareholder Returns - The company plans to distribute a cash dividend of RMB 13.01 per 10 shares, totaling approximately RMB 88.91 million, representing a cash dividend payout ratio of 50% for the year 2021[6]. - The cash dividend distribution plan has been approved by the board and will be submitted for shareholder approval[184]. - The company has a cash dividend policy that mandates a minimum of 10% of the distributable profits to be distributed as cash dividends annually, provided there are no major investment plans[182]. - The company confirmed that the dividend distribution plan complies with its articles of association and shareholder resolutions[185]. Operational Efficiency - The company aims to improve operational efficiency by implementing advanced manufacturing technologies and optimizing supply chain management[16]. - The company employs a "sales-driven procurement" model, aligning production with sales forecasts and inventory levels to optimize supply chain efficiency[49]. - The company plans to enhance its supply chain efficiency, aiming for a 15% reduction in operational costs by the end of 2022[153]. - The company achieved a 40% increase in operational efficiency through the integration of facial recognition technology in its products[82]. Market Trends and Industry Insights - The demand for rehabilitation medical devices is expected to continue growing due to factors such as an aging population and rising chronic disease prevalence, alongside the implementation of the two-child policy[55]. - The magnetic stimulation device market in China is still in its early stages, having begun to scale around 2016, with applications primarily in mental and neurological rehabilitation[56]. - The overall rehabilitation medical industry is expected to grow due to increasing national income and heightened awareness of healthcare among residents[65]. - The market for magnetic stimulation rehabilitation medical devices in China is projected to grow at a compound annual growth rate (CAGR) of 52.0%, reaching 1.78 billion CNY by 2023[129]. - The rehabilitation robot market in China is expected to grow at a CAGR of 57.5%, reaching 2.04 billion CNY by 2023, indicating significant growth potential[130].

Financial Performance - The total revenue for Q1 2022 was CNY 54,107,297.63, representing a year-on-year decrease of 32.53%[5] - The net profit attributable to shareholders was CNY 17,009,682.26, down 45.62% compared to the same period last year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 9,101,425.65, a decline of 64.88% year-on-year[5] - Basic earnings per share were CNY 0.2489, down 45.62% year-on-year[6] - Total operating revenue for Q1 2022 was ¥54,107,297.63, a decrease of 32.5% compared to ¥80,199,797.02 in Q1 2021[20] - Net profit for Q1 2022 was ¥17,009,682.26, a decline of 45.0% from ¥31,143,408.53 in Q1 2021[21] - Basic earnings per share for Q1 2022 were ¥0.2489, compared to ¥0.4577 in Q1 2021, reflecting a decrease of 45.6%[22] Cash Flow - The cash flow from operating activities was negative at CNY -4,026,720.88, reflecting a decrease of 165.22%[6] - Cash inflow from operating activities in Q1 2022 was ¥80,426,045.90, down 10.6% from ¥89,860,727.29 in Q1 2021[23] - The net cash flow from operating activities was -$4,026,720.88, a decrease compared to $6,173,884.92 in the previous year[24] - Total cash outflow from operating activities was $84,452,766.78, slightly higher than $83,686,842.37 in the previous year[24] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,633,238,657.53, a slight decrease of 0.34% from the end of the previous year[6] - As of March 31, 2022, the total current assets amounted to ¥1,420,724,782.34, a slight decrease from ¥1,434,334,932.56 at the end of 2021, reflecting a change of approximately -0.95%[16] - The total liabilities as of Q1 2022 were ¥81,056,182.35, down 23.4% from ¥105,679,873.40 in Q1 2021[20] - Current liabilities increased, with accounts payable rising to ¥9,547,293.70 from ¥9,279,529.62, an increase of approximately 2.9%[17] Research and Development - Research and development expenses totaled CNY 15,816,919.49, which is 29.23% of total revenue, an increase of 16.39 percentage points[6] - Research and development expenses for Q1 2022 were ¥12,926,343.65, an increase of 25.5% from ¥10,297,726.89 in Q1 2021[20] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 6,761[13] - The largest shareholder, Wang Zhiyu, holds 39.45% of the shares, totaling 26,961,547 shares[13] Other Information - The company implemented a restricted stock incentive plan, resulting in a post-tax share-based payment expense of CNY 3,954,600[7] - The company has ongoing investments in new technologies and product development, although specific figures were not disclosed in the report[15] - There are no significant changes in the shareholder structure or any new mergers and acquisitions reported during the quarter[15] - The company did not report any new product launches or significant market expansions during this quarter[24] - The company is not applying the new accounting standards for the current year[25]

Financial Performance - The company's operating revenue for Q3 2021 was ¥111,882,494.11, representing a year-on-year increase of 14.11%[5] - The net profit attributable to shareholders for Q3 2021 was ¥38,391,924.38, reflecting a year-on-year growth of 20.07%[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2021 was ¥32,880,595.77, an increase of 6.50% compared to the same period last year[5] - The net profit attributable to shareholders for the year-to-date period reached ¥107,573,509.85, a 25.66% increase year-on-year[6] - Net profit for the third quarter of 2021 was ¥107,307,555.26, representing a 25.9% increase from ¥85,231,353.21 in Q3 2020[24] - Earnings per share for the third quarter of 2021 were ¥1.5739, slightly up from ¥1.5549 in the same quarter of 2020[25] Research and Development - Total R&D investment for Q3 2021 was ¥18,342,651.82, which is an increase of 113.36% year-on-year[6] - R&D investment accounted for 16.39% of operating revenue in Q3 2021, up by 7.63 percentage points from the previous year[6] - Research and development expenses for the first three quarters of 2021 totaled ¥46,463,175.23, significantly higher than ¥23,862,728.01 in the previous year, indicating a focus on innovation[23] - The company has a significant focus on research and development, with ongoing projects aimed at enhancing product offerings and market expansion strategies[16] Cash Flow and Assets - The cash flow from operating activities for the year-to-date period increased by 64.59%, primarily due to the expansion of business scale[7] - The net cash flow from operating activities was 85,294,228.32 RMB, an increase of 64.5% compared to 51,823,350.77 RMB in the previous year[27] - The total cash inflow from investment activities reached 3,197,962,728.20 RMB, significantly up from 845,629,967.58 RMB, marking a growth of 277.5%[27] - The cash outflow for investment activities was 3,394,265,888.24 RMB, compared to 1,596,746,049.14 RMB, resulting in a net cash flow from investment activities of -196,303,160.04 RMB[27] - The total assets at the end of Q3 2021 were ¥1,566,608,441.44, a 1.70% increase from the end of the previous year[6] - The company's cash and cash equivalents decreased to RMB 1,171,940,014.84 from RMB 1,366,464,211.43, representing a decline of about 14.2%[18] - The total liabilities as of the end of Q3 2021 amounted to ¥105,285,395.96, compared to ¥129,453,569.35 at the end of the previous year[23] Future Outlook - Future guidance indicates a cautious optimism regarding revenue growth, driven by new product launches and market penetration efforts[16] - The company has indicated plans for market expansion and new product development as part of its future strategy[24] - The company is actively exploring potential mergers and acquisitions to strengthen its market position and expand its operational capabilities[16] Shareholder Information - The company reported a total of 3,509,288 shares held by Shenzhen Yanghe Biomedical Investment Co., Ltd., making it the largest unrestricted shareholder[15] Financial Management - The company reported a financial income of ¥12,001,146.74 in the first three quarters of 2021, compared to ¥3,034,198.92 in the previous year, reflecting improved financial management[23] - The total equity attributable to shareholders of the parent company was ¥1,459,495,216.08, up from ¥1,406,015,537.73 in the previous year[23] Liabilities and Equity - The total current liabilities decreased to RMB 102,971,270.62 from RMB 128,677,351.40, a reduction of about 20.0%[19] - The total liabilities were reported at 129,453,569.35 RMB, compared to 133,618,934.22 RMB previously[31] - The total equity attributable to shareholders was 1,406,015,537.73 RMB, remaining stable compared to the previous year[31] Changes in Accounting Standards - The company implemented new leasing standards starting from 2021, affecting the financial statements[28]

Financial Performance - The company reported a total revenue of RMB 100 million for the first half of 2021, reflecting a year-on-year growth of 20%[1]. - The company's operating revenue for the first half of 2021 was RMB 191.43 million, representing a year-on-year increase of 21.91%[21]. - The net profit attributable to shareholders for the same period was RMB 69.18 million, up 28.99% year-on-year, primarily due to increased sales[22]. - The net cash flow from operating activities surged by 329.87% to RMB 41.96 million, driven by expanded business scale[22]. - Basic earnings per share decreased by 3.26% to RMB 1.0122, while diluted earnings per share fell by 3.66% to RMB 1.0080[21]. - The company achieved total revenue of RMB 191.43 million in the first half of 2021, representing a year-on-year growth of 21.91%[85]. - Net profit attributable to shareholders reached RMB 69.18 million, an increase of 28.99% compared to the previous year[85]. Revenue Guidance and Projections - The company has set a revenue guidance of RMB 250 million for the full year 2021, representing a 25% increase from the previous year[1]. - The company provided a positive outlook for the second half of 2021, projecting a revenue growth of 30% year-on-year[110]. - New product launches are expected to contribute an additional 200 million yuan in revenue by the end of the year[110]. User Engagement and Market Expansion - User data indicates an increase in active users by 15% compared to the previous year, reaching a total of 500,000 active users[1]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2022[1]. - Market expansion plans include entering two new regions, which are projected to increase market share by 10%[110]. Research and Development - The company has invested RMB 20 million in R&D for new technologies in rehabilitation medicine, aiming for a 40% improvement in treatment efficiency[1]. - The company's R&D expenditure accounted for 14.69% of operating revenue, an increase of 4.97 percentage points compared to the previous year[21]. - The total R&D investment for the current period is approximately ¥28.12 million, representing an increase of 84.21% compared to the previous period[57]. - R&D investment as a percentage of operating revenue has increased to 14.69%, up from 9.72% in the previous period, indicating a significant focus on innovation[57]. - The company is actively involved in key national research projects, including the development of a stroke rehabilitation robot system, which is currently awaiting acceptance[54]. Product Development and Innovation - New product development includes the launch of a next-generation rehabilitation device, expected to enhance user engagement by 30%[1]. - The company is actively involved in the development of new products, including the MyOnyx and MyoTrac series, marketed as biofeedback devices[12]. - The company is actively developing rehabilitation robotics, with products like the Xwalk200/300 lower limb exoskeleton already in the registration process for market launch[30]. - The company has developed advanced technologies in electrical stimulation, including muscle electrical stimulation and biofeedback, enhancing the clinical application of low-frequency electrical stimulation[50]. - The company has made significant advancements in the integration of stroke rehabilitation robotics, with key technology projects completed and awaiting final acceptance[62]. Market Trends and Opportunities - The rehabilitation medical device market in China grew from RMB 11.5 billion in 2014 to RMB 28 billion in 2018, with a CAGR of 24.9%, and is expected to reach RMB 67 billion by 2023, growing at a CAGR of 19.1%[37]. - The demand for rehabilitation medical devices is driven by an aging population and increasing chronic disease prevalence, indicating a sustained growth trajectory for the industry[37]. - The prevalence of pelvic floor dysfunction among middle-aged women in Beijing is 65.24%, indicating a significant market potential for postpartum and pelvic floor rehabilitation services[46]. Strategic Acquisitions and Partnerships - A strategic acquisition of a local competitor is in progress, which is anticipated to increase the company's market share by 15%[1]. - The company has established partnerships with three leading hospitals to enhance product testing and validation processes[1]. - The company is considering strategic acquisitions to enhance its product portfolio, with a target of 500 million yuan for potential acquisitions[110]. Risk Management - The management highlighted potential risks including regulatory changes and market competition, which could impact future performance[1]. - The company is closely monitoring industry trends to mitigate risks related to technological innovation and market competition[82]. Shareholder Commitments and Governance - The company commits to maintaining shareholder value, with plans for a dividend payout of 100 million yuan in the next quarter[110]. - The company has refined its profit distribution policy in accordance with regulatory requirements, enhancing the decision-making process and specific dividend ratios[153]. - The company will ensure that all actions regarding shareholding reduction are in accordance with the Company Law and Securities Law of the People's Republic of China[132]. - The company has committed to strictly implement its dividend policy to ensure shareholder returns, with a focus on protecting the interests of minority shareholders[153]. Environmental and Social Responsibility - The company is not classified as a heavily polluting industry and complies with environmental regulations[103]. - There were no administrative penalties related to environmental issues during the reporting period[104]. - The company has implemented a waste classification system for solid waste management[103].

Financial Performance - Operating revenue for the period was ¥80,199,797.02, representing a year-on-year increase of 40.66%[5] - Net profit attributable to shareholders was ¥31,281,901.82, an increase of 84.17% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses was ¥25,912,028.42, up 72.51% year-on-year[5] - Basic earnings per share increased to ¥0.4577, a rise of 38.11% compared to the previous year[5] - The company reported a total comprehensive income for Q1 2021 of ¥31,281,901.82, compared to ¥16,985,782.80 in Q1 2020, indicating an 84.5% increase[25] - The total profit for Q1 2021 was ¥35,400,822.19, compared to ¥19,275,946.26 in Q1 2020, marking an 83.9% increase[24] - Net profit for Q1 2021 was ¥31,143,408.53, up 83.8% compared to ¥16,941,112.78 in Q1 2020[24] Cash Flow - The cash flow from operating activities was ¥6,173,884.92, a significant recovery from a negative cash flow of ¥30,313,831.85 in the same period last year[5] - The net cash flow from operating activities was ¥11,389,801.86 in Q1 2021, recovering from a net outflow of ¥22,227,738.05 in Q1 2020[31] - The total cash outflow from operating activities was ¥77,164,643.53 in Q1 2021, up from ¥69,187,602.38 in Q1 2020[31] - The company reported a net increase in cash and cash equivalents of -¥369,062,716.93 in Q1 2021, compared to -¥30,757,465.17 in Q1 2020[32] Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,548,283,276.52, an increase of 0.51% compared to the end of the previous year[5] - Total current assets amounted to RMB 1.42 billion, slightly up from RMB 1.42 billion at the end of 2020[17] - Current liabilities decreased to CNY 106,483,189.84 from CNY 128,677,351.40, reflecting a reduction of approximately 17.3%[18] - Total liabilities decreased to CNY 110,724,451.31 from CNY 129,453,569.35, a decrease of approximately 14.5%[19] - The company’s minority interests decreased by 60.69% to RMB 1.96 million due to the acquisition of partial equity in a subsidiary[14] - Total non-current liabilities reached 776,217.95, with no significant adjustments noted[42] Research and Development - R&D investment accounted for 12.84% of operating revenue, an increase of 1.24 percentage points compared to the previous year[7] - Research and development expenses increased by 55.69% to RMB 10.30 million, reflecting higher employee compensation[14] - Research and development expenses increased to ¥10,297,726.89, representing a 55.5% rise from ¥6,614,086.04 in Q1 2020[23] Shareholder Information - The total number of shareholders at the end of the reporting period was 6,275[9] - The top shareholder, Wang Zhiyu, holds 39.45% of the shares, totaling 26,961,547 shares[9] Investment Activities - Investment income surged by 207.02% to RMB 3.52 million, driven by increased investment in financial products[14] - Total cash inflow from investment activities was ¥688,409,472.62 in Q1 2021, significantly up from ¥227,374,566.19 in Q1 2020, marking a 202.5% increase[32] - The cash outflow for investment activities totaled ¥1,068,596,178.21 in Q1 2021, compared to ¥230,738,995.59 in Q1 2020, resulting in a net cash flow of -¥380,186,705.59[32] Other Financial Metrics - The weighted average return on net assets decreased by 4.39 percentage points to 2.20%[5] - The company achieved operating revenue of RMB 80.20 million in Q1 2021, representing a growth of 40.66% compared to the same period last year[12] - Total operating costs for Q1 2021 were ¥53,670,086.70, a 30.2% increase from ¥41,200,565.97 in Q1 2020[23] - The company reported an operating profit of ¥33,216,672.19 for Q1 2021, up 75.5% from ¥18,935,198.80 in Q1 2020[24]

Financial Performance - The company's operating revenue for 2020 was CNY 378.37 million, an increase of 18.66% compared to CNY 318.87 million in 2019[23]. - The net profit attributable to shareholders for 2020 was CNY 143.66 million, representing a growth of 44.07% from CNY 99.72 million in 2019[23]. - The net cash flow from operating activities for 2020 was CNY 120.76 million, a decrease of 14.64% compared to CNY 141.47 million in 2019[23]. - The company's total assets at the end of 2020 were CNY 1,540.44 million, up 281.09% from CNY 404.22 million at the end of 2019[23]. - The basic earnings per share for 2020 was CNY 2.4608, an increase of 26.50% from CNY 1.9453 in 2019[24]. - The company reported a total of CNY 15.31 million in non-recurring gains and losses for 2020, compared to CNY 5.22 million in 2019[27]. - The main business revenue increased by CNY 59.60 million to CNY 376.63 million, reflecting a growth of 18.80% compared to the previous year[89]. - The main business cost rose to CNY 99.53 million, an increase of 19.39% year-on-year[89]. - The gross profit margin for the main business slightly decreased by 0.13 percentage points to 73.57%[91]. - The revenue from magnetic stimulation products grew by 46.32% due to successful product development and market promotion[92]. - The revenue from electrophysiological products increased by 47.62%, driven by the launch of a new product and sales growth of existing products[92]. Research and Development - Research and development expenses accounted for 9.06% of operating revenue in 2020, an increase of 0.47 percentage points from 8.59% in 2019[24]. - The total R&D expenditure for the year was ¥34,287,376.78, representing a 25.21% increase compared to the previous year, with R&D expenditure as a percentage of operating income at 9.06%[56]. - The number of R&D personnel increased to 125, representing 22.81% of the total workforce, up from 17.67% in the previous year[64]. - The average salary of R&D personnel was 224,373.14 RMB, slightly up from 223,593.51 RMB in the previous year[64]. - The company has developed advanced technologies in electrical stimulation, magnetic stimulation, and rehabilitation robots, focusing on clinical applications and integration of various treatment techniques[50]. - The company is actively researching machine vision-based functional electrical stimulation and intelligent electrical stimulation technologies to enhance rehabilitation outcomes[50]. - The cognitive dysfunction treatment software II generation product is currently in the R&D phase, indicating ongoing innovation efforts[61]. - The company has launched several models of the Ruiyi II biological stimulation feedback device, with a total investment of ¥1,960,000 and a cumulative investment of ¥1,761,290[59]. - The company is developing a stroke rehabilitation robot system, which is expected to be completed in 2021 due to delays caused by the pandemic[55]. Market and Product Development - The company focuses on rehabilitation medical devices utilizing magnetic stimulation technology, including main equipment and supporting stimulation coils[13]. - The company reported advancements in rehabilitation robots that assist patients in regaining motor functions, integrating multiple disciplines such as robotics and control science[13]. - The company is developing new technologies for neuromuscular electrical stimulation to enhance muscle recovery and improve patient outcomes[14]. - The company aims to address postpartum recovery issues, including urinary incontinence and pelvic pain, through targeted rehabilitation training[13]. - The company is expanding its product line to include cognitive function rehabilitation tools for patients with learning and memory disorders[14]. - The company is exploring market expansion opportunities in the field of neurological rehabilitation, particularly for stroke and Parkinson's disease patients[13]. - The company is committed to research and development of transcranial magnetic stimulation (TMS) technology to treat various neurological conditions[14]. - The company is focusing on expanding its product lines in the fields of gynecology, rehabilitation, and non-medical institutions, targeting conditions such as stress urinary incontinence and pelvic organ prolapse[59]. - The company is leveraging artificial intelligence and big data technologies to enhance treatment effectiveness in rehabilitation[112]. - The company is exploring new business opportunities in transcranial magnetic therapy for depression and cognitive rehabilitation for dementia patients, as well as expanding into international markets[119]. Corporate Governance and Compliance - The company has received a standard unqualified audit report from Tianheng Accounting Firm[4]. - There are no non-operating fund occupations by controlling shareholders or related parties[7]. - The company does not have any special arrangements for corporate governance[6]. - The company has confirmed that all board members can guarantee the authenticity, accuracy, and completeness of the annual report[8]. - The company has established a clear framework for dividend distribution based on its financial health and investment needs[124]. - The company is focused on resolving related party transactions to enhance transparency and governance[131]. - The company is committed to addressing land ownership issues to mitigate potential legal risks[132]. - The company has outlined a strategy for dividend distribution to enhance shareholder value[132]. - The company is committed to transparency and accuracy in its disclosures, ensuring no false statements or omissions are made[185]. - The company will ensure compliance with the stock price stabilization plan for three years post-IPO, urging all related parties to fulfill their obligations[161]. Shareholder Commitments and Dividends - The company plans to distribute a cash dividend of RMB 10.51 per 10 shares, totaling approximately RMB 71.83 million, representing a 50% cash dividend payout ratio for 2020[5]. - The company commits to a minimum cash dividend distribution of 30% of the average distributable profit over the last three years post-IPO, provided there are no major investment plans[123]. - The company has achieved a consistent cash dividend ratio of 50% for the past three years, indicating stable profitability and shareholder returns[126]. - The company has outlined conditions under which it may opt for stock dividends if cash dividends exceed 10% of distributable profits[123]. - The company’s board has approved the dividend distribution plan, pending shareholder meeting approval[125]. - The company will ensure that any necessary related party transactions are conducted fairly and in accordance with legal and regulatory requirements[182]. - The company has pledged to avoid any misuse of company assets for unrelated investments or consumption activities[181]. - The company will publicly explain and apologize for any violations of these commitments, accepting regulatory measures if necessary[180]. - The company will ensure that any changes in shareholdings are disclosed in accordance with the law and will accept penalties for any violations[145]. - The company will comply with regulations regarding major violations that could lead to delisting, ensuring no share reduction during that period[133].